Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience, Inc. (SKYE)
:SKYE
SKYE Stock Chart & Stats
$1.53
-$0.06(-1.95%)
At close: 4:00 PM EST
$1.53
-$0.06(-1.95%)
Day’s Range― - ―
52-Week Range$1.14 - $5.96
Previous CloseN/A
Volume18.00K
Average Volume (3M)1.36M
Market Cap
$47.41M
Enterprise Value$117.56M
Total Cash (Recent Filing)$48.59M
Total Debt (Recent Filing)$367.54K
Price to Earnings (P/E)―
Beta2.94
Next Earnings
Nov 10, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding30,988,420
10 Day Avg. Volume298,166
30 Day Avg. Volume1,358,623
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-3.85
Enterprise Value/Market Cap2.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-194.07
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$9.71Price Target Upside534.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market PotentialGiven the sizable addressable market in the obesity space, even modest penetration could translate to significant upside for investors.
Safety ProfileNimacimab produced incremental, clinically meaningful weight loss without added safety liabilities when combined with semaglutide.
Weight Loss EfficacyThe new data highlighted that when nimacimab is combined with Wegovy, weight regain upon stopping treatment was directionally reduced compared to treatment with Wegovy alone.
Bears Say
Dose EfficacyMonotherapy efficacy was limited at the 200 mg dose, indicating suboptimal exposure.
Monotherapy PerformanceMonotherapy nimacimab did not meet the primary endpoint for weight loss.
Patient Baseline CharacteristicsImbalances in patient baseline characteristics could influence results.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience, Inc.’s price range in the past 12 months?
Skye Bioscience, Inc. lowest stock price was $1.14 and its highest was $5.96 in the past 12 months.
What is Skye Bioscience, Inc.’s market cap?
Skye Bioscience, Inc.’s market cap is $47.41M.
When is Skye Bioscience, Inc.’s upcoming earnings report date?
Skye Bioscience, Inc.’s upcoming earnings report date is Nov 10, 2025 which is today.
How were Skye Bioscience, Inc.’s earnings last quarter?
Skye Bioscience, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.32 by -$0.12.
Is Skye Bioscience, Inc. overvalued?
According to Wall Street analysts Skye Bioscience, Inc.’s price is currently Undervalued.
Does Skye Bioscience, Inc. pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
What is Skye Bioscience, Inc.’s EPS estimate?
Skye Bioscience, Inc.’s EPS estimate is -0.31.
How many shares outstanding does Skye Bioscience, Inc. have?
Skye Bioscience, Inc. has 30,988,420 shares outstanding.
What happened to Skye Bioscience, Inc.’s price movement after its last earnings report?
Skye Bioscience, Inc. reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.32. Following the earnings report the stock price went down -0.845%.
Which hedge fund is a major shareholder of Skye Bioscience, Inc.?
Currently, no hedge funds are holding shares in SKYE
Skye Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.71 (534.64% Upside)
$9.71 (534.64% Upside)
Blogger Sentiment
Bullish
SKYE Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.87%
12-Months-Change
Fundamentals
Return on Equity
-72.75%
Trailing 12-Months
Asset Growth
-40.22%
Trailing 12-Months
Company Description
Skye Bioscience, Inc.
Skye Bioscience (SKYE) is a biotechnology company focused on the discovery, development, and commercialization of innovative pharmaceutical products intended to address unmet needs in various therapeutic areas. The company primarily operates in the biopharmaceutical sector, with a core emphasis on ocular diseases. Skye Bioscience is committed to advancing its pipeline of cannabinoid-derived compounds, leveraging its proprietary technologies to develop novel treatments that have the potential to improve patient outcomes.
SKYE Company Deck
SKYE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of Skye Bioscience's progress. While the company showcased significant advancements in its clinical trials and financial stability, it also faced challenges with increased R&D expenses and a substantial net loss. The strategic developments and promising preclinical data are positive highlights, but the enrollment challenges in the extension study indicate areas needing attention.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$9.71
▲(534.64% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
65.22% Insiders
3.77% Mutual Funds
0.18% Other Institutional Investors
27.42% Public Companies and Individual Investors